NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/14/2026
Back to search
Official data from USPTO
REMUNITYPRO FOR REMODULIN (TREPROSTINIL) INJECTION
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
27
Latest update
04/15/2026
Trademark type
Combined
Nice classes
10
Filing date
06/13/2024
Registration date
04/14/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/14/2026
Last transaction
04/15/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
04/07/2025
First use in commerce
04/07/2025
Drawing code
3
Owner type
03
Owner location
Silver Spring, MD, US
Examiner
KOLODNER, LOUIS FRANCIS
Law office
N40
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of "REMUNITYPRO FOR REMODULIN (TREPROSTINIL) INJECTION" in stylized font to the right of three overlapping open circles formed by dots of varying sizes.
Holders and representatives
Holders
U. C. (pessoa física)
Representatives
Norm J. Rich Foley & Lardner LLP
Technical classification
Nice Classes
Class 10
Vienna Codes
No Vienna codes available.
Goods and services
Class 10
Drug delivery systemspump injectors for the subcutaneous delivery of medication
Publications
History of USPTO decisions and trademark events.
27 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
04/14/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
03/26/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
03/26/2026
SUPC
STATEMENT OF USE PROCESSING COMPLETE
03/26/2026
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
03/26/2026
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/24/2025
IUAF
USE AMENDMENT FILED
09/23/2025
EISU
TEAS STATEMENT OF USE RECEIVED
09/23/2025
EX1G
SOU EXTENSION 1 GRANTED
09/23/2025
EXT1
SOU EXTENSION 1 FILED
09/23/2025
EEXT
SOU TEAS EXTENSION RECEIVED
09/23/2025
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
04/01/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/04/2025
PUBO
PUBLISHED FOR OPPOSITION
02/04/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/29/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/14/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
01/14/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/14/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
01/14/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/14/2025
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
01/14/2025
DOCK
ASSIGNED TO EXAMINER
01/13/2025
DOCK
ASSIGNED TO EXAMINER
01/03/2025
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
01/02/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/02/2025
NWAP
NEW APPLICATION ENTERED
06/13/2024
Continuous trademark protection
Get notified about every new filing that threatens REMUNITYPRO FOR REMODULIN (TREPROSTINIL) INJECTION or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.